Condition (MeSH)
Subcutaneous Emphysema
ClinicalTrials.gov lists 142 trials for Subcutaneous Emphysema or a narrower condition beneath it. Grifols Therapeutics LLC has the most among industry and government lead sponsors, with 12.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
1 more section with rows
7 of the 142 trials are tagged with Subcutaneous Emphysema itself; the rest are tagged with a narrower condition beneath it.
When did Subcutaneous Emphysema trials start? (30)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 9
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 9 |
| 2025 | 8 |
| 2024 | 9 |
| 2023 | 7 |
| 2022 | 6 |
| 2021 | 4 |
| 2020 | 5 |
| 2019 | 9 |
| 2018 | 8 |
| 2017 | 7 |
Showing 10 of 30 earlier years.
Forecast of the full-year count, planned starts included, not rows of this table: about 9 trials starting in 2026 and about 8 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Prediction, not a registry value: median of 36 months from start to primary completion across 13 trials still running at the 2026-10-09 snapshot; registered median of 27 months across 84 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Subcutaneous Emphysema trials in? (9)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 19 |
| Phase 1/2 | 14 |
| Phase 2 | 25 |
| Phase 2/3 | 2 |
| Phase 3 | 11 |
| Phase 4 | 9 |
| Not applicable | 13 |
| Observational | 48 |
| Expanded access | 1 |
How many Subcutaneous Emphysema trials are recruiting? (10)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 6 |
| Recruiting | 18 |
| Enrolling by invitation | 3 |
| Active, not recruiting | 7 |
| Completed | 68 |
Showing 5 of 10 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Subcutaneous Emphysema trials? (10)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Grifols Therapeutics LLC | 12 |
| Baxalta now part of Shire | 8 |
| Arrowhead Pharmaceuticals | 5 |
| Takeda | 5 |
| Vertex Pharmaceuticals Incorporated | 5 |
Showing 5 of 10 sponsors.
Which drugs are being tested for Subcutaneous Emphysema? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Belcesiran | 3 |
| Fazirsiran | 3 |
Interventions as named in the registry (13)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Alpha1-antitrypsin | 18 |
| Alpha-1 MP | 5 |
| Liver biopsy | 2 |
| rAAV1-CB-hAAT | 2 |
| SAR447537 | 2 |
Showing 5 of 13 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Subcutaneous Emphysema trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Chronic obstructive pulmonary disease | 44 | 7 |
| Pneumonia | 31 | 9 |
| Abdominal Pain | 14 | 1 |
| Lower respiratory tract infection | 9 | 2 |
| Pneumothorax | 9 | 5 |
Showing 5 of 10 adverse events.
Which publications cover Subcutaneous Emphysema? (18)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Comparison of valve-less and standard insufflation on pneumoperitoneum-related complications in robotic partial nephrectomy: a prospective randomized trial. | Journal of robotic surgery | 2021 | Yes |
| COVID-19 with spontaneous pneumothorax, pneumomediastinum and subcutaneous emphysema. | Journal of travel medicine | 2020 | Yes |
| Spontaneous pneumomediastinum, pneumothorax and subcutaneous emphysema in COVID-19 pneumonia: a rare case and literature review. | BMJ case reports | 2020 | Yes |
| Clinical predictors of occult pneumothoraces in severely injured blunt polytrauma patients: A prospective observational study. | Injury | 2009 | Yes |
| Subcutaneous scalp emphysema, pneumo-orbitis and pneumocephalus in a neonate on high humidity high flow nasal cannula. | Journal of perinatology : official journal of the California Perinatal Association | 2008 | Yes |
Showing 5 of 18 publications.
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.